Drugs /

lsz102

Back to Drugs List

Overview

NCI Definition [1]:
An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.

Clinical Trials

View Clinical Trials for lsz102

Lsz102 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lsz102, 1 is phase 1 (1 open).

ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for lsz102 clinical trials.

Breast carcinoma is the most common disease being investigated in lsz102 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lsz102
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lsz102 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
serd lsz102, selective estrogen receptor degraderlsz102, lsz 102, serd lsz 102, selective estrogen receptor degrader lsz102
NCIT ID [1]:
C128280

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.